acf/google-ad-placement

<ul>
	<li><strong>AbbVie Inc</strong>&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/abbv#NYSE" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">ABBV</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.prnewswire.com/news-releases/mitokinin-inc-enters-into-purchase-right-agreement-with-abbvie-301238053.html" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">landed an option to buy Mitokinin</a>&nbsp;upon completing IND-enabling studies on the latter&#39;s lead PINK1 compound for Parkinson&#39;s disease.</li>
	<li>Mitokinin&#39;s novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson&#39;s disease.</li>
	<li>Mitokinin is based on technology discovered by Nicholas Hertz, Ph.D., and Kevan Shokat, Ph.D., at the University of California, San Francisco.</li>
	<li>Now, AbbVie has signed up to help Mitokinin get to the next stage in its evolution. In return for the option to buy Mitokinin, AbbVie is making an upfront payment.</li>
	<li><strong>Price Action:</strong>&nbsp;ABBV shares are up 0.1% at $108.5 in market trading hours on the last check Tuesday.</li>
</ul>


Biotech

Comments